Boston, June 24

Welcome to HubXchange’s Boston CNS Therapeutics Xchange 2024, bringing together executives from pharma and biotech to address and find solutions to the key issues faced in developing CNS therapies.
Discussion topics will cover Novel Targets, Preclinical, Clinical Studies and Drug Delivery.
Take advantage of this unique highly interactive meeting format designed for maximum engagement, collaboration and networking with your peers.

Please note this is an In-Person meeting. 

VENUE DETAILS: Woburn Hilton Hotel, 2 Forbes Road, Woburn, MA, 01801, US


  • Leveraging in vivo phenotypic screens for novel target discovery in neurological disorders
  • Utilizing AI-powered drug discovery to unravel novel CNS targets
  • Implementing novel preclinical organoid and in vivo models to investigate subtype-selectivity and cross-species activity of CNS therapeutics.
  • Preclinical validation of gene and cell therapies for CNS diseases
  • Implementing precision medicine trial designs to overcome the challenge of small and heterogeneous patient populations in rare diseases
  • Application of digital biomarkers in clinical trials
  • RNA design and delivery optimization to treat CNS diseases
  • Non-invasive drug delivery for CNS indications

Full Xchange Agenda

Click on each track for detailed agenda

Novel Targets

Titles and Bullets
8:00 – 8:30

8:30 – 9:00

Opening Address & Keynote Presentation

9:05 – 10:05

Leveraging in vivo phenotypic screens for novel target discovery in neurological disorders

  • Unbiased, phenotype-driven drug discovery to identify most potent novel targets benchmarked against other targets & existing therapies
  • Novel target discovery in in vivo animal models vs. in vitro cell-based experiments
  • Translatability of novel targets of phenotypic screens into clinic
  • Generating complementary in vivo and in vitro neuropharmacology datasets to inform clinical trial designs

Dr Shane Hegarty is Chief Scientific Officer, Founder and Inventor at AXONIS Therapeutics, Boston-based biotechnology company. 14+ years of experience leading cutting-edge, award-winning neuro-protection, -modulation and -regeneration research for neurological disorders. As Research Fellow in Boston Children’s Hospital/Harvard Medical School, led genome-wide AAV-CRISPR screen for neuro-protection and -regeneration in vivo within Professor Zhigang He’s lab. Before US, he was Faculty Member in Neuroscience Department of University College Cork, Ireland, and received prestigious Neuroscience Ireland Investigator Award. Highly-productive researcher with 30+ publications, >1,400 citations, h-index=18, and serial grant awardee. Experienced entrepreneur, innovator, editor, peer-reviewer, university lecturer, research supervisor, and team manager/mentor.

Shane Hegarty
10:10 – 10:40
1-2-1 Meetings/Networking Break
10:40 – 11:10
1-2-1 Meetings / Networking Break
11:10 – 11:20
Morning Refreshments
12:20 – 13:20

Networking Lunch

13:20 – 13:50

Spotlight Presentation

13:55 – 14:25

1-2-1 Meetings / Networking Break

14:25 – 14:55

1-2-1 Meetings / Networking Break

15:00 – 15:30

Poster Presentation

15:35 – 16:35

Utilizing AI-powered drug discovery to unravel novel CNS targets

16:35 – 17:35
Evening Drinks Reception


CNS Therapeutics Xchange | Boston 2024